Table 1.
Baseline patient characteristics
| Characteristic | N = 18 |
|---|---|
| On-study age—years | |
| Median | 57 |
| Range | 25—81 |
| Sex-no. (%) | |
| Female | 10 (56) |
| Male | 8 (44) |
| Ethnicity-no. (%) | |
| Non-hispanic white | 7 (39) |
| Non-hispanic African-American | 6 (33) |
| Other | 5 (28) |
| Primary site (%)* | |
| Left colon/rectum | 11 (61) |
| Right colon | 6 (33) |
| Histologic grade | |
| Well differentiated | 0 (0) |
| Moderately differentiated | 14 (78) |
| Poorly differentiated | 2 (11) |
| Unknown | 2 (11) |
| Time from metastatic diagnosis-months | |
| Median | 32 |
| Range | 4—172 |
| Metastatic site (%) | |
| Liver only | 4 |
| Lymph nodes only | 1 |
| Bladder only | 1 |
| Multiple sites | 12 |
| Exposure to prior therapies (%) | |
| Fluoropyrimidine | 18 (94) |
| Oxaliplatin | 17 (94) |
| Irinotecan | 17 (94) |
| Anti-VEGF | 17 (94) |
| Anti-EGFR | 8 (44) |
| KRAS mutation status | |
| Wild-type | 7 |
| Mutant | 9 |
| Unknown | 2 |
| Microsatellite Instability/Mismatch Repair Status | |
| MSI-H/dMMR | 1 |
| MSS/pMMR | 12 |
| Unknown | 5 |
*Unable to verify site of primary in 1 patient